A A A A
 
Pages
Meet The Team How-Tos Our Supporters How to Participate in Precision Panc Membership Meeting Minutes Remit of Steering Committee Patient Stories Documents Working with the NHS Patient Public Engagement Meetings Governance News Clinicians Area Clinical Trials What is precision medicine? Information and Support What is Pancreatic Cancer? Current Research Our Researchers Privacy Policy Patients and Carers Contact Us About us Home
Posts
Precision-Panc Recruits Patient 250 Marking World Pancreatic Cancer Day Precision-Panc working with myTomorrows Precision-Panc Roundtable Final Report New Glasgow Cancer Assays by GPOL and Agilent Technologies Precision-Panc opens site 25! Precision-Panc Summer Newsletter Precision-Panc Recruits Patient 200! Precision-Panc Brochure Royal Bournemouth Hospital Opens Finding the right treatment for the patient CRUK animate the Precision-Panc platform CRUK / Precision-Panc Video Professor Biankin receives the Order of Australia in Queen’s Birthday Honours Precision-Panc opens its 20th Site Precision Panc Spring Newsletter Precision-Panc Opens Site 19 Recent Media Pieces Regarding 100 Patient Milestone Site 17 opens for Precision-Panc PRIMUS 002 opens Informing the Future of Genomic Medicine in Scotland Report is Published St James’s University Hospital Opens Precision-Panc Opens its 15th site Glasgow Experts Lead UK Pancreatic Cancer Research 11th site opens to PRECISION-Panc Scotsman Conferences Blogspot November is Pancreatic Cancer Awareness Month First Precision-Panc Trial Opens In Glasgow Cancer Research UK Investment Landscape of pancreatic neuroendocrine cancer Whole Genome Sequencing from EUS biopsies Upcoming Pancreas 2016 Conference Scottish Genome Partnership Announced Identification of four Pancreatic Cancer subtypes offers new treatment insight into the disease First Minister announces £4m ‘Precision Medicine Ecosystem’
Menu
 
 
Home | News | New Glasgow Cancer Assays by GPOL and Agilent Technologies

New Glasgow Cancer Assays by GPOL and Agilent Technologies

Published: 14th November 2019


GPOL at the University of Glasgow has developed the groundbreaking new Glasgow Cancer Assays a suite of affordable, fit-for-purpose, solid and haematological cancer genomic assays, developed specifically to address the challenges of real-world oncology, both for current and emerging routine healthcare and for therapeutic development, including participant selection for clinical trials and discovering markers of response and resistance.


The Glasgow Cancer Assays are currently being evaluated by NHS labs in England and Scotland. Agilent Technologies has been granted a non-exclusive licence for global distribution

“The Glasgow Cancer Assays were created so that every patient with cancer could have access to the latest treatments and clinical trials,” said Professor Andrew Biakin. “Our team of inventors, including Susie Cooke, Philip Beer and David Chang, have dedicated the last five years of their lives to creating the Glasgow Cancer test. This test will enable patients around the world to access the best treatments for their cancer. I’m extremely proud of what the team have done and where this might take us for healthcare in the future.”

For more information click here

© 2019 Precision Panc
Web design by Creatomatic
This site uses cookies.
Configure
 
Read our privacy policy

This site uses cookies for marketing, personalisation, and analysis purposes. You can opt out of this at any time or view our full privacy policy for more information.